Food and Drug Administration Approval Summary: Odevixibat (Bylvay) for the Treatment of Pruritus With Progressive Familial Intrahepatic Cholestasis
On July 20, 2021, the Food and Drug Administration approved odevixibat (Bylvay) for the treatment of pruritus in patients 3 months of age and older with progressive familial intrahepatic cholestasis (PFIC). PFIC is a rare disease that results in impaired bile secretion and transport, leading to chol...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-01-01
|
| Series: | Gastro Hep Advances |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2772572324001924 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850259363507208192 |
|---|---|
| author | Sojeong Yi Insook Kim Rebecca Hager Marian M. Strazzeri Lili Garrard Toru Matsubayashi Ruby Mehta |
| author_facet | Sojeong Yi Insook Kim Rebecca Hager Marian M. Strazzeri Lili Garrard Toru Matsubayashi Ruby Mehta |
| author_sort | Sojeong Yi |
| collection | DOAJ |
| description | On July 20, 2021, the Food and Drug Administration approved odevixibat (Bylvay) for the treatment of pruritus in patients 3 months of age and older with progressive familial intrahepatic cholestasis (PFIC). PFIC is a rare disease that results in impaired bile secretion and transport, leading to cholestatic liver injury. Odevixibat is a reversible inhibitor of the ileal bile acid transporter. It decreases the reabsorption of bile acids from the terminal ileum (distal small intestines). Approval was based on the improvement in pruritus demonstrated in a 24-week randomized double-blind placebo-controlled trial conducted in 62 pediatric subjects, aged 6 months to 17 years, with a confirmed molecular diagnosis of PFIC type 1 or type 2 with the presence of pruritus at baseline. Given the subjects’ young age, a single-item observer-reported outcome (ObsRO) was used to measure scratching as observed by the caregiver. Subjects had an average scratching score of greater than or equal to 2 (medium scratching) in the 2 weeks before baseline. The mean percentage of ObsRO assessments over the 24-week treatment period that were scored as 0 (no scratching) or 1 (a little scratching) was 35.4% and 30.1% for 40 mcg/kg/day and 120 mcg/kg/day odevixibat treatment, respectively, compared to 13.2% for placebo. There was general alignment between subject and caregiver assessments of worst weekly pruritus severity among subjects for whom both patient-reported outcome (Worst Weekly Itching Score) and ObsRO (Worst Weekly Scratching Score) data were available. The most common adverse reactions included diarrhea, liver test abnormalities, vomiting, abdominal pain, and fat-soluble vitamin deficiency. The benefit-risk assessment for odevixibat for the treatment of pruritus in the labeled population was considered favorable. |
| format | Article |
| id | doaj-art-b7e7313e527342b1a68e5b1d34a151ca |
| institution | OA Journals |
| issn | 2772-5723 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Gastro Hep Advances |
| spelling | doaj-art-b7e7313e527342b1a68e5b1d34a151ca2025-08-20T01:55:52ZengElsevierGastro Hep Advances2772-57232025-01-014410059610.1016/j.gastha.2024.100596Food and Drug Administration Approval Summary: Odevixibat (Bylvay) for the Treatment of Pruritus With Progressive Familial Intrahepatic CholestasisSojeong Yi0Insook Kim1Rebecca Hager2Marian M. Strazzeri3Lili Garrard4Toru Matsubayashi5Ruby Mehta6Division of Inflammation and Immune Pharmacology, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research (CDER), The U.S. Food and Drug Administration (FDA), Silver Spring, MarylandDivision of Inflammation and Immune Pharmacology, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research (CDER), The U.S. Food and Drug Administration (FDA), Silver Spring, MarylandDivision of Biostatistics III, Office of Biostatistics, Office of Translational Sciences, CDER, FDA, Silver Spring, MarylandDivision of Biostatistics III, Office of Biostatistics, Office of Translational Sciences, CDER, FDA, Silver Spring, MarylandDivision of Biostatistics III, Office of Biostatistics, Office of Translational Sciences, CDER, FDA, Silver Spring, MarylandDivision of Hepatology and Nutrition, Office of Immunology and Inflammation, Office of New Drugs, CDER, FDA, Silver Spring, MarylandDivision of Hepatology and Nutrition, Office of Immunology and Inflammation, Office of New Drugs, CDER, FDA, Silver Spring, Maryland; Correspondence: Address correspondence to: Ruby Mehta, MD, Division of Hepatology and Nutrition, Office of Immunology and Inflammation, Office of New Drugs, CDER, FDA, WO-22, Room 5327, 10903 New Hampshire Ave, Silver Spring, Maryland 20993.On July 20, 2021, the Food and Drug Administration approved odevixibat (Bylvay) for the treatment of pruritus in patients 3 months of age and older with progressive familial intrahepatic cholestasis (PFIC). PFIC is a rare disease that results in impaired bile secretion and transport, leading to cholestatic liver injury. Odevixibat is a reversible inhibitor of the ileal bile acid transporter. It decreases the reabsorption of bile acids from the terminal ileum (distal small intestines). Approval was based on the improvement in pruritus demonstrated in a 24-week randomized double-blind placebo-controlled trial conducted in 62 pediatric subjects, aged 6 months to 17 years, with a confirmed molecular diagnosis of PFIC type 1 or type 2 with the presence of pruritus at baseline. Given the subjects’ young age, a single-item observer-reported outcome (ObsRO) was used to measure scratching as observed by the caregiver. Subjects had an average scratching score of greater than or equal to 2 (medium scratching) in the 2 weeks before baseline. The mean percentage of ObsRO assessments over the 24-week treatment period that were scored as 0 (no scratching) or 1 (a little scratching) was 35.4% and 30.1% for 40 mcg/kg/day and 120 mcg/kg/day odevixibat treatment, respectively, compared to 13.2% for placebo. There was general alignment between subject and caregiver assessments of worst weekly pruritus severity among subjects for whom both patient-reported outcome (Worst Weekly Itching Score) and ObsRO (Worst Weekly Scratching Score) data were available. The most common adverse reactions included diarrhea, liver test abnormalities, vomiting, abdominal pain, and fat-soluble vitamin deficiency. The benefit-risk assessment for odevixibat for the treatment of pruritus in the labeled population was considered favorable.http://www.sciencedirect.com/science/article/pii/S2772572324001924Clinical Outcome Assessment (COA)PruritusItchingProgressive Familial Intrahepatic Cholestasis (PFIC)Adverse Events (AE) |
| spellingShingle | Sojeong Yi Insook Kim Rebecca Hager Marian M. Strazzeri Lili Garrard Toru Matsubayashi Ruby Mehta Food and Drug Administration Approval Summary: Odevixibat (Bylvay) for the Treatment of Pruritus With Progressive Familial Intrahepatic Cholestasis Gastro Hep Advances Clinical Outcome Assessment (COA) Pruritus Itching Progressive Familial Intrahepatic Cholestasis (PFIC) Adverse Events (AE) |
| title | Food and Drug Administration Approval Summary: Odevixibat (Bylvay) for the Treatment of Pruritus With Progressive Familial Intrahepatic Cholestasis |
| title_full | Food and Drug Administration Approval Summary: Odevixibat (Bylvay) for the Treatment of Pruritus With Progressive Familial Intrahepatic Cholestasis |
| title_fullStr | Food and Drug Administration Approval Summary: Odevixibat (Bylvay) for the Treatment of Pruritus With Progressive Familial Intrahepatic Cholestasis |
| title_full_unstemmed | Food and Drug Administration Approval Summary: Odevixibat (Bylvay) for the Treatment of Pruritus With Progressive Familial Intrahepatic Cholestasis |
| title_short | Food and Drug Administration Approval Summary: Odevixibat (Bylvay) for the Treatment of Pruritus With Progressive Familial Intrahepatic Cholestasis |
| title_sort | food and drug administration approval summary odevixibat bylvay for the treatment of pruritus with progressive familial intrahepatic cholestasis |
| topic | Clinical Outcome Assessment (COA) Pruritus Itching Progressive Familial Intrahepatic Cholestasis (PFIC) Adverse Events (AE) |
| url | http://www.sciencedirect.com/science/article/pii/S2772572324001924 |
| work_keys_str_mv | AT sojeongyi foodanddrugadministrationapprovalsummaryodevixibatbylvayforthetreatmentofprurituswithprogressivefamilialintrahepaticcholestasis AT insookkim foodanddrugadministrationapprovalsummaryodevixibatbylvayforthetreatmentofprurituswithprogressivefamilialintrahepaticcholestasis AT rebeccahager foodanddrugadministrationapprovalsummaryodevixibatbylvayforthetreatmentofprurituswithprogressivefamilialintrahepaticcholestasis AT marianmstrazzeri foodanddrugadministrationapprovalsummaryodevixibatbylvayforthetreatmentofprurituswithprogressivefamilialintrahepaticcholestasis AT liligarrard foodanddrugadministrationapprovalsummaryodevixibatbylvayforthetreatmentofprurituswithprogressivefamilialintrahepaticcholestasis AT torumatsubayashi foodanddrugadministrationapprovalsummaryodevixibatbylvayforthetreatmentofprurituswithprogressivefamilialintrahepaticcholestasis AT rubymehta foodanddrugadministrationapprovalsummaryodevixibatbylvayforthetreatmentofprurituswithprogressivefamilialintrahepaticcholestasis |